ReviewMediators of inflammation1998
Topical glucocorticoids and the skin--mechanisms of action: an update.
Review in Mediators of inflammation, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Topical anti-inflammatory treatments for eczema: network meta-analysis.The Cochrane database of systematic reviews · 2024Pooled it
- Interventions for bullous pemphigoid.The Cochrane database of systematic reviews · 2023Pooled it
- Strategies for using topical corticosteroids in children and adults with eczema.The Cochrane database of systematic reviews · 2022Pooled it
- Interventions for treating oral lichen planus: corticosteroid therapies.The Cochrane database of systematic reviews · 2020Pooled it
- Interventions for hand eczema.The Cochrane database of systematic reviews · 2019Pooled it
- Topical clobetasol propionate 0.025% oral gel in the treatment of oral lichen planus: a double-blind, randomized placebo-controlled trial.BMC oral health · 2026Trial
- Topical pimecrolimus versus betamethasone for oral lichen planus: a randomized clinical trial.Clinical oral investigations · 2019Trial
- Antisense molecules: A promising new therapy for atopic dermatitis.Acta pharmaceutica Sinica. B · 2025Review
- Effect of Topical Corticosteroid Treatment on microRNA Expression in Infants with Atopic Dermatitis.JID innovations : skin science from molecules to population health · 2025Article
- Exosomes and Exosome-Mimetics for Atopic Dermatitis Therapy.Tissue engineering and regenerative medicine · 2025Review
- Poly(lactic Acid) Fibers for Sustained Drug Delivery: Insights into Release Profiles and Cellular Interactions.Materials (Basel, Switzerland) · 2025Article
- Article
- Hydrocortisone treatment as a tool to study conjunctival placode induction.Developmental dynamics : an official publication of the American Association of Anatomists · 2025Article
- Adult-onset inflammatory linear verrucous epidermal nevus successfully treated with intralesional steroid.JAAD case reports · 2024Article
- Neuropsychiatric Systemic Lupus Erythematosus: Molecules Involved in Its Imunopathogenesis, Clinical Features, and Treatment.Molecules (Basel, Switzerland) · 2024Review
- Glucocorticoids Do Not Affect the Vascular Component of TRP-Mediated Neurogenic Skin Inflammation.Journal of inflammation research · 2024Article
- Visualization of Nanocarriers and Drugs in Cells and Tissue.Handbook of experimental pharmacology · 2024Article
- The role of dexamethasone in mediating the contradictory effects of Wnt antagonists SFRP2 and SFRP3 on human hair follicle growth.Scientific reports · 2023Article
- Article
- Tough Adhesive Hydrogel for Intraoral Adhesion and Drug Delivery.Journal of dental research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The topical glucocorticoids (GCs) represent the treatment of choice for many types of inflammatory dermatoses. Despite the extensive use of this class of drugs as first line therapy the mechanism of their action is uncertain. It is clear that the multiplicity of actions of the topical GCs is an important facet of their scope in the treatment of dermal disorders. The aim of this update is to review past and current theories regarding how these agents might work. Current understanding of the molecular mechanisms of GC action has advanced significantly over the past decade with the realisation that multiple systems are responsible for transduction of GC effects at a molecular level. The two primary modes of action are via interaction directly with DNA or indirectly through modulation of specific transcription factors: the endpoint in both cases being modulation of specific protein synthesis. Both of these mechanisms will be discussed. In particular this review will concentrate on the possibility that a GC-inducible protein, termed lipocortin 1, may have a significant role to play in the anti-inflammatory actions of these drugs. Additionally it has become apparent that several inflammatory enzymes induced in inflammation are sites of inhibitory action of the GCs, and the possibility that this occurs in the skin will be discussed paying particular attention to the inducible phospholipase A2, nitric oxide synthase and cyclooxygenase systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.